ICU Medical initiated with bullish view at CL King, here’s why

CL King initiated coverage of ICU Medical with a Buy rating and $110 price target. The firm expects ICU Medical’s earnings to trough in FY24 and to see a marked recovery in FY25 as gross margins normalize, the analyst tells investors in a research note. CL King sees a favorable risk/reward profile given current expectations and the stock’s valuation.